MODIFICATION
A -- NIAID Structural Genomics Centers for Infectious Diseases
- Notice Date
- 7/10/2006
- Notice Type
- Modification
- NAICS
- 541710
— Research and Development in the Physical, Engineering, and Life Sciences
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Office of Acquisitions 6700 B Rockledge Room 3214 MSC7612, Bethesda, MD, 20892-7612
- ZIP Code
- 20892-7612
- Solicitation Number
- SS-NIH-NIAID-DMID-07-19
- Response Due
- 7/21/2006
- Archive Date
- 8/5/2006
- Description
- THIS NOTICE IS FOR INFORMATION AND PLANNING PURPOSES ONLY. THIS IS NOT A REQUEST FOR PROPOSALS AND DOES NOT COMMIT THE GOVERNMENT TO AWARD A CONTRACT NOW OR IN THE FUTURE. NO SOLICITATION IS AVAILABLE AT THIS TIME. BASED ON CAPABILITY STATEMENTS RECEIVED FROM THIS SOURCES SOUGHT NOTICE, THIS ACQUISITION MAY BE SOLICITED AS A 100% SMALL BUSINESS SET-ASIDE OR AS FULL AND OPEN. ALL SMALL BUSINESS ORGANIZATIONS (SB, SDB, WOSB, HUBZone, VOSB, and SDVOSB) ARE ENCOURAGED TO RESPOND TO THIS NOTICE. SMALL BUSINESS ORGANIZATIONS MUST HAVE THEIR SIZE STATUS CERTIFIED BY THE SMALL BUSINESS ADMINISTRATION. THE NAICS CODE IS 541710 WITH A SIZE STANDARD OF 500 EMPLOYEES. The National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH), of the Department of Health and Human Services (DHHS) supports research related to the basic understanding of microbiology and immunology leading to the development of vaccines, therapeutics, and medical diagnostics for the prevention, treatment, and diagnosis of infectious diseases. The NIAID, Division of Microbiology and Infectious Diseases (DMID), supports a comprehensive extramural research program focused on the prevention and control of diseases caused by virtually all infectious agents (with the exception of the Human Immunodeficiency Virus). This includes basic research, such as studies of microbial biology and physiology; applied research, including the development of vaccines, therapeutics and medical diagnostics; as well as clinical studies to evaluate experimental drugs and vaccines. To build upon the objectives of the NIAID Genomics programs (http://www.niaid.nih.gov/dmid/genomes/) and address the Institute?s need to further expand the knowledge of the proteome, NIAID is looking to establish 2 large scale Structural Genomics Centers for Infectious Diseases that will apply state-of-the art high-throughput (HTP) structural biology technologies to experimentally characterize the three dimensional atomic structure of targeted proteins from pathogens in the NIAID Category A-C priority lists (http://www3.niaid.nih.gov/biodefense/bandc_priority.htm) and organisms causing emerging and re-emerging infectious diseases. The scope of the Structural Genomics Centers for Infectious Diseases is to create a collection of high quality, experimentally determined three-dimensional structures that is widely available to the scientific community and serves as a blueprint for development of structure-based drugs, vaccines and diagnostics for infectious diseases. The three dimensional structure of proteins can assist drug design and development by yielding direct insights into the target molecular mechanisms, in interaction with other biological molecules, or with synthetic compounds, in order to improve selectivity, specificity and optimize drug development in a rational way. The primary focus of the Structural Genomics Centers shall be pathogen targets that are expected to have an important biological role and a potential impact on biomedical research, such as: Proteins involved in pathogenesis, such as invasins, adhesions, toxins; Proteins essential to the pathogen?s life and reproductive cycle; Proteins involved in antimicrobial/drug resistance; Protein markers of acute or chronic infection; Complexes with natural substrates, cofactors, receptors, drug candidates; Protein splice variants, post-translational modifications and other functionally characterized variants. HTP structure determination is a complex scientific and technical process that includes target selection, cloning, expression and purification, sample preparation for X-ray crystallography and nuclear magnetic resonance (NMR) spectroscopy, X-ray and NMR data collection, structure solution and validation. Pathogen targets shall be proposed by external investigators, NIH, other Government agencies, and the Contractor. The Contractor is expected to provide NIAID with established operational facilities, infrastructure, and scientific and technical expertise to perform in a HTP manner every component of the protein structure determination process. The Center shall provide to the broad scientific community by making available its technologies, resources and staff expertise to determine the structure of targets and deposit that information into the public domain. The Center must maintain productivity, quality and costs for structure determination that are competitive with those of similar HTP Structural Genomics Centers, such as the Large-Scale Centers funded by the NIH National Institute of General Medical Sciences (NIGMS) under the second phase of the Protein Structure Initiative (PSI-2) http://www.nigms.nih.gov/Initiatives/PSI/. NIAID is committed to release into the public domain the results of the structural genomics projects in a timely fashion. It is anticipated that the Contractor will follow the guidelines established by the NIGMS-PSI large scale Centers for structural genomics. Those guidelines currently state that the atomic coordinates of the three-dimensional structure of biological macromolecules and associated data shall be deposited and released into the public domain within 4 weeks from completion of the structure determination project. The Government anticipates multiple awards. It is anticipated that the duration of the contracts will be a maximum of five (5) years; however, the length of time for which funding is requested should be consistent with the nature and complexity of the proposed research. Small business and 8(a) contractors are reminded that in order to quality as a set-aside, 51% of the direct labor must be performed by the prime contractor. It is anticipated that an anticipated total effort of approximately 29.75 FTEs will be needed to accomplish this project. Interested organizations should submit three (3) copies of their capability statement addressing each of the areas cited above. Interested organizations presenting a capability statement in response to this sources sought announcement must identify their size status. Written capability statements should be received by the NIAID Contracting Officer by July 21, 2006. Please reference the solicitation number on all related correspondence. No collect calls or facsimiles will be accepted. E-mail transmissions will be accepted. Any proprietary information should be so marked. See Government-wide numbered note 25.
- Record
- SN01085484-W 20060712/060710220319 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |